Published in Neurosci Lett on August 10, 2012
The challenges and the promise of molecular targeted therapy in malignant gliomas. Neoplasia (2015) 0.96
Sui generis: gene therapy and delivery systems for the treatment of glioblastoma. Neuro Oncol (2015) 0.94
New treatment strategies to eradicate cancer stem cells and niches in glioblastoma. Neurol Med Chir (Tokyo) (2013) 0.77
The Methanol Extract of Angelica sinensis Induces Cell Apoptosis and Suppresses Tumor Growth in Human Malignant Brain Tumors. Evid Based Complement Alternat Med (2013) 0.76
Intratumoral hemorrhage-related differences in the expression of vascular endothelial growth factor, basic fibroblast growth factor and thioredoxin reductase 1 in human glioblastoma. Mol Clin Oncol (2016) 0.75
Antitumor activity of combined endostatin and thymidine kinase gene therapy in C6 glioma models. Cancer Med (2016) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med (2005) 29.65
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Angiogenic factors. Science (1987) 15.22
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Tumorigenesis and the angiogenic switch. Nat Rev Cancer (2003) 11.95
Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet (2003) 6.95
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 5.54
A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A (1990) 5.26
Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res (2000) 4.89
Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem (1978) 3.29
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science (1990) 3.02
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 2.67
Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res (2008) 2.64
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res (2006) 2.42
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
The brain tumor microenvironment. Glia (2011) 2.13
Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res (1996) 1.94
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem (2008) 1.93
A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene (1997) 1.88
Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 1.78
Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A (2000) 1.76
VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther (2007) 1.75
Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med (2004) 1.70
Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res (2000) 1.70
Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther (2009) 1.69
Innate and adaptive autoimmunity directed to the central nervous system. Neuron (2009) 1.66
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor. Oncogene (2005) 1.61
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist (2007) 1.58
Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood (2009) 1.57
In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J (2001) 1.55
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs (2009) 1.47
Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene (1997) 1.47
Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res (2006) 1.47
An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol (2001) 1.46
Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood (2000) 1.45
Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther (2001) 1.45
Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin. J Neurosurg (2011) 1.42
HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther (2005) 1.42
Complement in the brain. Mol Immunol (2011) 1.41
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
The host response to cancer virotherapy. Curr Opin Mol Ther (2008) 1.36
Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs (2010) 1.34
Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther (2003) 1.31
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther (2006) 1.29
Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res (1999) 1.28
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am J Pathol (2003) 1.21
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. J Neurosurg (1994) 1.19
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther (2009) 1.16
Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther (2005) 1.16
Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants. New Biol (1990) 1.13
The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol (2000) 1.12
Comparative study of angiostatic and anti-invasive gene expressions as prognostic factors in gastric cancer. Int J Oncol (2001) 1.11
The challenge for gene therapy: innate immune response to adenoviruses. Oncotarget (2011) 1.10
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther (2006) 1.09
Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther (2008) 1.09
Brain-specific angiogenesis inhibitor 1 expression is inversely correlated with vascularity and distant metastasis of colorectal cancer. Int J Oncol (1998) 1.09
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res (2006) 1.09
Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer (2005) 1.08
Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. Blood (1998) 1.08
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 1.07
Nonviral approaches for neuronal delivery of nucleic acids. Pharm Res (2007) 1.07
Structural and functional comparison of the genes for human platelet factor 4 and PF4alt. Blood (1990) 1.07
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol (2012) 1.06
Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U S A (2000) 1.06
Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene (2008) 1.06
Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med (1997) 1.05
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther (2011) 1.05
Antiangiogenic gene therapy of cancer: recent developments. J Transl Med (2004) 1.03
Vascularization is decreased in pulmonary adenocarcinoma expressing brain-specific angiogenesis inhibitor 1 (BAI1). Int J Mol Med (2000) 1.03
Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression. Cancer Res (2005) 1.02
Angiostatin suppresses malignant glioma growth in vivo. Cancer Res (1998) 1.02
The discovery of angiogenic factors: a historical review. Gen Pharmacol (2000) 1.01
Toll-like receptors in inflammation of the central nervous system. Int Immunopharmacol (2011) 1.00
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol (2010) 0.99
Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. Oncol Rep (2007) 0.99
Antitumor efficacy of AAV-mediated systemic delivery of interferon-beta. Cancer Gene Ther (2006) 0.99
Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res (2001) 0.98
Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 0.98
Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther (2006) 0.97
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res (2003) 0.97
Gene therapy of intracranial glioma using interleukin 12-secreting human umbilical cord blood-derived mesenchymal stem cells. Hum Gene Ther (2011) 0.96
Molecular therapeutic targets for glioma angiogenesis. J Oncol (2010) 0.96
Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res (2002) 0.96
Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res (1996) 0.95
Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther (2010) 0.95
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res (2004) 2.79
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst (2007) 2.46
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res (2006) 2.42
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33
Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol (2004) 2.21
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Infectious delivery of a 135-kb LDLR genomic locus leads to regulated complementation of low-density lipoprotein receptor deficiency in human cells. Mol Ther (2003) 1.78
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J Clin Oncol (2011) 1.71
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res (2002) 1.62
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther (2008) 1.59
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med (2012) 1.52
Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther (2004) 1.51
Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol (2008) 1.47
Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res (2006) 1.47
Emerging functions of microRNAs in glioblastoma. J Neurooncol (2009) 1.44
microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell Cycle (2010) 1.40
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol (2002) 1.29
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61. Mol Ther (2008) 1.28
Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res (2005) 1.26
MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. Neuro Oncol (2013) 1.20
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin Cancer Res (2004) 1.19
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci U S A (2012) 1.18
Extracellular vesicles and their convergence with viral pathways. Adv Virol (2012) 1.18
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther (2009) 1.16
Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol Ther (2005) 1.16
The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther (2002) 1.14
Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev (2010) 1.13
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets (2007) 1.11
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J Theor Biol (2009) 1.10
In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology (2002) 1.09
An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08
Quantitative analysis of complex glioma cell migration on electrospun polycaprolactone using time-lapse microscopy. Tissue Eng Part C Methods (2009) 1.08
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Mol Ther (2013) 1.07
Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. Cancer Res (2005) 1.07
Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev (2010) 1.06
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol Ther (2011) 1.05
Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors. Front Biosci (2003) 1.04
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
MRI of transgene expression: correlation to therapeutic gene expression. Neoplasia (2002) 1.03
In-training factors predictive of choosing and sustaining a productive academic career path in neurological surgery. Neurosurgery (2012) 1.03
Regulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5. J Clin Invest (2002) 1.03
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res (2011) 1.02
Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther (2004) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma. Cancer Res (2012) 1.01
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. Cancer Res (2014) 1.00
Lack of epidural pressure change with neck flexion in a patient with Hirayama disease: case report. Neurosurgery (2009) 0.99
Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med (2003) 0.99
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations. Cancer Res (2013) 0.99
Oral tocotrienols are transported to human tissues and delay the progression of the model for end-stage liver disease score in patients. J Nutr (2012) 0.99
Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 0.98
C2/C3 pathologic fractures from polyostotic fibrous dysplasia of the cervical spine treated with percutaneous vertebroplasty. Eur Spine J (2007) 0.97
PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res (2003) 0.97
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol (2010) 0.97
Cytomegalovirus infection leads to pleomorphic rhabdomyosarcomas in Trp53+/- mice. Cancer Res (2012) 0.96
A retrospective cohort-matched comparison of conscious sedation versus general anesthesia for supratentorial glioma resection. Clinical article. J Neurosurg (2010) 0.96
The status of gene therapy for brain tumors. Expert Opin Biol Ther (2007) 0.95
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov (2009) 0.94
Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer (2002) 0.93
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res (2012) 0.92
Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther (2009) 0.91
Functional response of tumor vasculature to PaCO2: determination of total and microvascular blood volume by MRI. Neoplasia (2003) 0.91
Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density. J Biol Chem (2013) 0.91
Intra-arterial delivery of p53-containing adenoviral vector into experimental brain tumors. Cancer Gene Ther (2002) 0.91
Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther (2007) 0.90
Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS One (2013) 0.90
Clinical and economic outcomes of low-field intraoperative MRI-guided tumor resection neurosurgery. J Magn Reson Imaging (2011) 0.89
Strategies in gene therapy for glioblastoma. Cancers (Basel) (2013) 0.87